Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03173950
Title Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

high grade glioma

gliosarcoma

pineoblastoma

choroid plexus papilloma

chordoma

brain stem glioma

meningioma

choroid plexus carcinoma

gliomatosis cerebri

atypical teratoid rhabdoid tumor

high grade ependymoma

brain sarcoma

medulloblastoma

Therapies

Nivolumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UC San Diego Recruiting La Jolla California 92093-0603 United States Details
UC Irvine Recruiting Orange California 92668 United States Details
Orlando Health Recruiting Orlando Florida 32806 United States Details
Northwestern University Recruiting Chicago Illinois 60611 United States Details
NorthShore University Medical Center Recruiting Evanston Illinois 60201 United States Details
National Institutes of Health Clinical Center Recruiting Bethesda Maryland 20892 United States Details
Washington University of St. Louis Recruiting Saint Louis Missouri 63110 United States Details
Ohio State University Recruiting Columbus Ohio 43210-1240 United States Details
University of Pittsburgh Recruiting Pittsburgh Pennsylvania 15261 United States Details
Medical University of South Carolina Recruiting Charleston South Carolina 29425 United States Details
UT MD Anderson Cancer Center Recruiting Houston Texas 77030-4096 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field